PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)

Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as antineoplastic agent >20 years ago, only a few phase III randomized trials have shown challenging data regarding different therapeutic options for facing its aggressive clinical course and granting activ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology letters 2020-10, Vol.20 (4), p.1-1
Hauptverfasser:	Loizzi, Vera, Ranieri, Girolamo, Laforgia, Mariarita, Gadaleta, Cosmo Damiano, Gargano, Giulio, Kardhashi, Anila, Liso, Maria De, Naglieri, Emanuele, Vecchio, Vittoria Del, Cicinelli, Ettore, Cormio, Gennaro
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Bevacizumab Breast cancer Care and treatment Drug approval Health aspects Immunotherapy Kinases Medical research Monoclonal antibodies Monosaccharides Mutation Olaparib Oncology Ovarian cancer Prognosis Respiratory system agents Review Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!